Skip to main content

Table 2 Identification of KRAS mutation in patient cohorts using different methods

From: A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients

Cohort Total KRAS Mutation Identified (Codon 12 & 61) Method Tumour Type KRAS Mutation Frequency Total KRAS mutation Frequency
Discovery Cohort (n = 8) N = 1 NGS PDAC (n = 5) 0% 12%
PAC (n = 3) 33% (n = 1)
Validation Cohort (n = 85)/ (n = 75)a N = 16 Sanger Sequencing PDAC (n = 25) 32%(n = 8) 19%
PAC (n = 50) 14% (n = 6)
PCR-RFLP of 12th Codon PDAC (n = 25) 32%(n = 8) 19%
PAC (n = 50) 14% (n = 6)
ASPCR PDAC (n = 25) 36%(n = 9) 20%
PAC (n = 50) 12% (n = 6)
Independent Patient Cohort (n = 24) N = 8 PCR-RFLP of 12th Codon PDAC (n = 24) 33% (n = 8) 33%
  1. aIn case of validation cohort PCR amplification of KRAS exon 2 for 10 samples could not performed due to technical error